Developer docs
API playgroundTry for free, no card

Search company profiles

Oncostellae

Full company profile

uuid0002a4w

Namestring
Oncostellae
Legal namestring
ONCOSTELLAE, S.L.
Websiteurl
oncostellae.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Oncostellae is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Santiago de Compostela, Galicia, Spain. The company discovers and develops proprietary small-molecule drug candidates targeting high unmet medical needs in immunology and oncology, with active programs in inflammatory bowel disease (ulcerative colitis), women's health (uterine fibroids), colorectal cancer, and fibrosis. It was founded by Dr. Mabel Loza, a researcher from the University of Santiago de Compostela, and biotech entrepreneur Julio Castro, whose prior deal-making track record includes the Oryzon-Roche €525M licensing transaction (2014) and the Palobiofarma-Novartis acquisition (2015). The company operates with a lean team of 1-10 employees.

The pipeline consists of three proprietary drug candidates. The lead asset, OST-122, is an oral, gut-restricted JAK3/TYK2/ARK5 inhibitor designed to act exclusively in the gastrointestinal tract, achieving millimolar fecal concentrations while maintaining plasma levels below 1 ng/mL; it successfully completed Phase 2a proof-of-concept in 36 ulcerative colitis patients and was tolerated up to 1,200 mg in Phase 1. OST-499 is an oral, non-steroidal progesterone receptor and glucocorticoid receptor antagonist in Phase 1 for uterine fibroids and colon cancer (subsequently carved out into Oriva Therapeutics in January 2026). OST-664 is an oral ARK5 inhibitor in late discovery (~70% complete) for fibrosis. Patent applications are pending at the European Patent Office for ALK5 inhibitors and GR antagonists developed under the IO4COLON project. The central technical differentiator is the company’s GI-restricted drug delivery platform, which directly addresses FDA safety concerns regarding systemic JAK inhibitors (infections, thromboembolism, cardiac events).

Oncostellae’s business model is licensing-centric and asset-light: the company develops candidates from conception through Phase I/II and then outlicenses further development and commercialization rights to large or mid-size pharmaceutical partners in exchange for upfront payments, development milestones, and royalties. The company has no commercial products and generates no product revenue. Business development is conducted primarily through participation in international biotech partnering conferences (BIO-Europe, BIO Digital, Biospain, BIO Investor Day). Cumulative disclosed private funding totals approximately €5.65M across rounds in 2017, 2022, 2024, and 2025, supplemented by a €2.39M CDTI Seal of Excellence grant for OST-122 development in 2025-2026. The 2024 European Commission Seal of Excellence under Horizon Europe EIC Accelerator provides external validation of OST-122’s regulatory positioning.

Short descriptiontext

Oncostellae is a clinical-stage Spanish biopharmaceutical company developing proprietary small-molecule drug candidates—most notably the gut-restricted JAK inhibitor OST-122—for inflammatory bowel disease, oncology, and fibrosis, and outlicensing clinical-stage assets to pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSantiago De Compostela, Spain
HQ citystring
Santiago De Compostela
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, small-molecule drug discovery, kinase inhibitor development, inflammatory bowel disease therapeutics, drug outlicensing services
Industry3 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biopharmaceutical drug discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Outlicensing
TypeLicensing Royalties
Description

Oncostellae's business model is based on discovering new drug candidates, developing them through Phase I/II clinical trials, and then outlicensing further development and commercialization rights to established pharmaceutical companies. The company receives upfront payments, milestone payments tied to development progress, and royalty payments on future sales.

oncostellae.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Oncostellae is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule drug candidates (kinase inhibitors and receptor antagonists) for inflammatory bowel disease, uterine fibroids, colon cancer and fibrosis. It advances candidates through Phase I/II clinical trials and then outlicenses further development and commercialization rights to large pharmaceutical companies in exchange for upfront, milestone and royalty payments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2a study demonstrated excellent safety profile with minimal systemic absorption in 36 patients with moderate to severe ulcerative colitis over 4-week treatment period
+2 more records
Product overview1 text field

Oncostellae is a clinical-stage biopharmaceutical company pioneering the discovery and development of proprietary small-molecule drug candidates addressing high unmet medical needs in immunology and oncology. The company's product portfolio consists of three distinct drug candidates: OST-122 (lead product) is a gut-restricted JAK3/TYK2-ARK5 inhibitor in Phase IIa for inflammatory bowel disease; OST-499 is a non-steroidal PR/GR antagonist in Phase I for uterine fibroids and colon cancer; and OST-664 is an ARK5 inhibitor in discovery phase for fibrosis. Oncostellae develops clinical candidates from conception through Phase I/II, with further development and commercialization rights licensed to pharmaceutical companies.

Product and service3 records
1OST-122
CategorySmall-molecule kinase inhibitor drug candidate
Description

Oral, non-systemic (gut-restricted) JAK3/TYK2/ARK5 inhibitor for the local treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis. Designed to act exclusively in the gastrointestinal tract, avoiding severe systemic toxicities (infections, thromboembolism, cardiac events) associated with FDA-approved systemic JAK inhibitors. Successfully completed Phase 2a proof-of-concept.

2OST-499
CategorySmall-molecule receptor antagonist drug candidate
Description

Oral, non-steroidal progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist in Phase 1 clinical trials for the treatment of uterine fibroids, other gynecological disorders and colon cancer.

3OST-664
CategorySmall-molecule kinase inhibitor drug candidate
Description

Oral ARK5 inhibitor in discovery phase (70% complete) for the treatment of fibrosis.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Oriva Therapeutics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Spin-off company launched by Asabys that incorporated two advanced assets from Oncostellae (ORV-362 for endometriosis and ORV-499 for uterine fibroids) as part of a women's health-focused biotech company. Oncostellae's OST-499 program became part of Oriva's pipeline.

capital-riesgo.es
2University of Santiago de Compostela
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic institution supporting the IO4COLON project consortium, providing research infrastructure and expertise for discovery of immunotherapeutic drugs for colon cancer treatment.

oncostellae.com
3LEITAT Technology Center
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Technology center supporting the IO4COLON project with expertise in technological development and innovation for new therapeutic product discovery.

oncostellae.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Galician biotech company specializing in organic synthesis and medicinal chemistry. Long-standing collaboration partner in the Neogalfarma and IO4COLON consortia, contributing research programs in prostate and breast cancer alongside Oncostellae.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Galician biotech company providing analytical technology platform capabilities. Core consortium partner in Neogalfarma and IO4COLON projects, developing analytical methods including HPLC-MS/MS for detection of kinase inhibitors and glucocorticoid receptor antagonists.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Galician biotech company specialized in nanomaterials with potential antitumor effects. Joined the Neogalfarma consortium in 2016, bringing nanotechnology capabilities to expand the portfolio of cancer treatments under development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing small molecules for chronic inflammatory and autoimmune diseases, including IMU-856 (gut-restricted, targeting S1P receptor modulator) for inflammatory bowel disease. Directly comparable to Oncostellae as both pursue gut-restricted oral therapies for IBD with similar safety-focused differentiation strategies.

TypeDirect peer
Description

Clinical-stage biotech developing oral gut-restricted therapeutics for IBD, including omilancor (LANCL2 agonist) and LABP-104. Comparable to Oncostellae as both pursue oral, locally-acting small molecules designed to minimize systemic exposure for UC and Crohn's disease.

TypeDirect peer
Description

European biotech that developed and out-licensed filgotinib (JAK1 inhibitor) to Gilead for IBD and other inflammatory indications. Galapagos shares Oncostellae's combination of European roots, JAK inhibitor focus in IBD, and outlicensing business model.

TypeRegional player
Description

Spanish clinical-stage epigenetics company whose lead asset (vafidemstat) was previously licensed to Roche in a €525M deal (2014). Closely comparable Spanish biotech with a similar small-molecule clinical-stage profile, founded around the same time as Oncostellae, and connected to co-founder Julio Castro's track record.

5Palobiofarma
TypeRegional player
Description

Spanish biotech developing adenosine receptor modulators and other small molecules for oncology and inflammatory diseases, which was acquired by Novartis in 2015. Comparable Spanish small-molecule biotech with a similar licensing/exit pathway and connection to Oncostellae co-founder Julio Castro's network.

TypeBroad incumbent
Description

Global biopharmaceutical company marketing upadacitinib (Rinvoq), a systemic JAK1 inhibitor approved for ulcerative colitis. Represents the established systemic JAK approach that OST-122's gut-restricted profile is designed to differentiate against, and a likely outlicensing counterparty.

TypeBroad incumbent
Description

Global pharma that developed and markets tofacitinib (Xeljanz), the first-in-class JAK inhibitor and the asset at the center of the FDA's systemic JAK safety scrutiny. Comparable as a potential licensing partner for OST-122 given its established IBD commercial infrastructure.

TypeBroad incumbent
Description

Global pharma marketing baricitinib (Olumiant), a systemic JAK inhibitor co-developed with Incyte for inflammatory and autoimmune indications. Comparable as a large-pharma reference point for JAK inhibitor class dynamics and a potential partner for Oncostellae's gut-restricted asset.

TypeEmerging player
Description

Specialty biopharma focused on developing and commercializing small-molecule therapeutics for inflammatory and respiratory diseases. Comparable mid-sized clinical/commercial-stage biopharma with a similar outlicensing/partnering orientation in inflammatory disease.

TypeEmerging player
Description

European specialty pharmaceutical company focused on gastroenterology and hepatology, including developing locally-acting drugs for IBD. Comparable as a European specialist GI therapeutics company and a potential regional licensing partner for OST-122.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncostellae

Clinical-stage biopharmaceutical drug discoveryoncostellae.com

Oncostellae is a clinical-stage Spanish biopharmaceutical company developing proprietary small-molecule drug candidates—most notably the gut-restricted JAK inhibitor OST-122—for inflammatory bowel disease, oncology, and fibrosis, and outlicensing clinical-stage assets to pharmaceutical partners.

What Oncostellae does

Oncostellae is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Santiago de Compostela, Galicia, Spain. The company discovers and develops proprietary small-molecule drug candidates targeting high unmet medical needs in immunology and oncology, with active programs in inflammatory bowel disease (ulcerative colitis), women's health (uterine fibroids), colorectal cancer, and fibrosis. It was founded by Dr. Mabel Loza, a researcher from the University of Santiago de Compostela, and biotech entrepreneur Julio Castro, whose prior deal-making track record includes the Oryzon-Roche €525M licensing transaction (2014) and the Palobiofarma-Novartis acquisition (2015). The company operates with a lean team of 1-10 employees.

The pipeline consists of three proprietary drug candidates. The lead asset, OST-122, is an oral, gut-restricted JAK3/TYK2/ARK5 inhibitor designed to act exclusively in the gastrointestinal tract, achieving millimolar fecal concentrations while maintaining plasma levels below 1 ng/mL; it successfully completed Phase 2a proof-of-concept in 36 ulcerative colitis patients and was tolerated up to 1,200 mg in Phase 1. OST-499 is an oral, non-steroidal progesterone receptor and glucocorticoid receptor antagonist in Phase 1 for uterine fibroids and colon cancer (subsequently carved out into Oriva Therapeutics in January 2026). OST-664 is an oral ARK5 inhibitor in late discovery (~70% complete) for fibrosis. Patent applications are pending at the European Patent Office for ALK5 inhibitors and GR antagonists developed under the IO4COLON project. The central technical differentiator is the company’s GI-restricted drug delivery platform, which directly addresses FDA safety concerns regarding systemic JAK inhibitors (infections, thromboembolism, cardiac events).

Oncostellae’s business model is licensing-centric and asset-light: the company develops candidates from conception through Phase I/II and then outlicenses further development and commercialization rights to large or mid-size pharmaceutical partners in exchange for upfront payments, development milestones, and royalties. The company has no commercial products and generates no product revenue. Business development is conducted primarily through participation in international biotech partnering conferences (BIO-Europe, BIO Digital, Biospain, BIO Investor Day). Cumulative disclosed private funding totals approximately €5.65M across rounds in 2017, 2022, 2024, and 2025, supplemented by a €2.39M CDTI Seal of Excellence grant for OST-122 development in 2025-2026. The 2024 European Commission Seal of Excellence under Horizon Europe EIC Accelerator provides external validation of OST-122’s regulatory positioning.

Oncostellae firmographics

Firmographics
Name
Oncostellae
Legal name
ONCOSTELLAE, S.L.
Website
https://oncostellae.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Oncostellae is a clinical-stage Spanish biopharmaceutical company developing proprietary small-molecule drug candidates—most notably the gut-restricted JAK inhibitor OST-122—for inflammatory bowel disease, oncology, and fibrosis, and outlicensing clinical-stage assets to pharmaceutical partners.
Ownership category
akta.pro rank

Oncostellae industry classification

Industry
Product category
Clinical-stage biopharmaceutical drug discovery
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • Small-molecule drug discovery
  • Kinase inhibitor development
  • Inflammatory bowel disease therapeutics
  • Drug outlicensing services

Where Oncostellae is headquartered

Location

Headquarters

HQ city
Santiago De Compostela
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Oncostellae business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Outlicensing: Oncostellae's business model is based on discovering new drug candidates, developing them through Phase I/II clinical trials, and then outlicensing further development and commercialization rights to established pharmaceutical companies. The company receives upfront payments, milestone payments tied to development progress, and royalty payments on future sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Oncostellae product offering

Product offering

Core offering

Oncostellae is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule drug candidates (kinase inhibitors and receptor antagonists) for inflammatory bowel disease, uterine fibroids, colon cancer and fibrosis. It advances candidates through Phase I/II clinical trials and then outlicenses further development and commercialization rights to large pharmaceutical companies in exchange for upfront, milestone and royalty payments.

Product overview

Oncostellae is a clinical-stage biopharmaceutical company pioneering the discovery and development of proprietary small-molecule drug candidates addressing high unmet medical needs in immunology and oncology. The company's product portfolio consists of three distinct drug candidates: OST-122 (lead product) is a gut-restricted JAK3/TYK2-ARK5 inhibitor in Phase IIa for inflammatory bowel disease; OST-499 is a non-steroidal PR/GR antagonist in Phase I for uterine fibroids and colon cancer; and OST-664 is an ARK5 inhibitor in discovery phase for fibrosis. Oncostellae develops clinical candidates from conception through Phase I/II, with further development and commercialization rights licensed to pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • OST-122 Oral, non-systemic (gut-restricted) JAK3/TYK2/ARK5 inhibitor for the local treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis. Designed to act exclusively in the gastrointestinal tract, avoiding severe systemic toxicities (infections, thromboembolism, cardiac events) associated with FDA-approved systemic JAK inhibitors. Successfully completed Phase 2a proof-of-concept.
  • OST-499 Oral, non-steroidal progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist in Phase 1 clinical trials for the treatment of uterine fibroids, other gynecological disorders and colon cancer.
  • OST-664 Oral ARK5 inhibitor in discovery phase (70% complete) for the treatment of fibrosis.

Quantifiable outcome

  • Phase 2a study demonstrated excellent safety profile with minimal systemic absorption in 36 patients with moderate to severe ulcerative colitis over 4-week treatment period
  • +2 more outcomes

Companies that use Oncostellae

Customer profile

Segments4 records

Ideal customer profiles1 record

Oncostellae technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Oncostellae partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Oriva TherapeuticsminorStrategic or Co-development Partner · 1 January 2026Spin-off company launched by Asabys that incorporated two advanced assets from Oncostellae (ORV-362 for endometriosis and ORV-499 for uterine fibroids) as part of a women's health-focused biotech company. Oncostellae's OST-499 program became part of Oriva's pipeline.
  • University of Santiago de CompostelaminorStrategic or Co-development Partner · 1 January 2021Academic institution supporting the IO4COLON project consortium, providing research infrastructure and expertise for discovery of immunotherapeutic drugs for colon cancer treatment.
  • LEITAT Technology CenterminorStrategic or Co-development Partner · 1 January 2021Technology center supporting the IO4COLON project with expertise in technological development and innovation for new therapeutic product discovery.
  • GalChimiacoreStrategic or Co-development Partner · 1 January 2018Galician biotech company specializing in organic synthesis and medicinal chemistry. Long-standing collaboration partner in the Neogalfarma and IO4COLON consortia, contributing research programs in prostate and breast cancer alongside Oncostellae.
  • AMSLabcoreStrategic or Co-development Partner · 1 January 2018Galician biotech company providing analytical technology platform capabilities. Core consortium partner in Neogalfarma and IO4COLON projects, developing analytical methods including HPLC-MS/MS for detection of kinase inhibitors and glucocorticoid receptor antagonists.
  • NanogapminorStrategic or Co-development Partner · 1 January 2016Galician biotech company specialized in nanomaterials with potential antitumor effects. Joined the Neogalfarma consortium in 2016, bringing nanotechnology capabilities to expand the portfolio of cancer treatments under development.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Oncostellae competitors and assessment

Company assessment

Direct peers

  • Immunic Therapeutics: Clinical-stage biotech developing small molecules for chronic inflammatory and autoimmune diseases, including IMU-856 (gut-restricted, targeting S1P receptor modulator) for inflammatory bowel disease. Directly comparable to Oncostellae as both pursue gut-restricted oral therapies for IBD with similar safety-focused differentiation strategies.
  • Landos Biopharma: Clinical-stage biotech developing oral gut-restricted therapeutics for IBD, including omilancor (LANCL2 agonist) and LABP-104. Comparable to Oncostellae as both pursue oral, locally-acting small molecules designed to minimize systemic exposure for UC and Crohn's disease.
  • Galapagos NV: European biotech that developed and out-licensed filgotinib (JAK1 inhibitor) to Gilead for IBD and other inflammatory indications. Galapagos shares Oncostellae's combination of European roots, JAK inhibitor focus in IBD, and outlicensing business model.

Regional players

  • Oryzon Genomics: Spanish clinical-stage epigenetics company whose lead asset (vafidemstat) was previously licensed to Roche in a €525M deal (2014). Closely comparable Spanish biotech with a similar small-molecule clinical-stage profile, founded around the same time as Oncostellae, and connected to co-founder Julio Castro's track record.
  • Palobiofarma: Spanish biotech developing adenosine receptor modulators and other small molecules for oncology and inflammatory diseases, which was acquired by Novartis in 2015. Comparable Spanish small-molecule biotech with a similar licensing/exit pathway and connection to Oncostellae co-founder Julio Castro's network.

Broad incumbents

  • AbbVie: Global biopharmaceutical company marketing upadacitinib (Rinvoq), a systemic JAK1 inhibitor approved for ulcerative colitis. Represents the established systemic JAK approach that OST-122's gut-restricted profile is designed to differentiate against, and a likely outlicensing counterparty.
  • Pfizer: Global pharma that developed and markets tofacitinib (Xeljanz), the first-in-class JAK inhibitor and the asset at the center of the FDA's systemic JAK safety scrutiny. Comparable as a potential licensing partner for OST-122 given its established IBD commercial infrastructure.
  • Eli Lilly: Global pharma marketing baricitinib (Olumiant), a systemic JAK inhibitor co-developed with Incyte for inflammatory and autoimmune indications. Comparable as a large-pharma reference point for JAK inhibitor class dynamics and a potential partner for Oncostellae's gut-restricted asset.

Emerging players

  • Theravance Biopharma: Specialty biopharma focused on developing and commercializing small-molecule therapeutics for inflammatory and respiratory diseases. Comparable mid-sized clinical/commercial-stage biopharma with a similar outlicensing/partnering orientation in inflammatory disease.
  • Dr. Falk Pharma: European specialty pharmaceutical company focused on gastroenterology and hepatology, including developing locally-acting drugs for IBD. Comparable as a European specialist GI therapeutics company and a potential regional licensing partner for OST-122.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks1 record

Key highlights6 records

Customer concentration

Oncostellae social profiles

Digital presence

Oncostellae financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncostellae leadership team

Management profile

Number of profiles

Profiles6 records

Oncostellae funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncostellae M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncostellae

What does Oncostellae do?

Oncostellae is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule drug candidates (kinase inhibitors and receptor antagonists) for inflammatory bowel disease, uterine fibroids, colon cancer and fibrosis. It advances candidates through Phase I/II clinical trials and then outlicenses further development and commercialization rights to large pharmaceutical companies in exchange for upfront, milestone and royalty payments.

Is Oncostellae a public or private company?

Oncostellae is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oncostellae founded?

Oncostellae was founded in 2013. It employs 1 to 10 people.

Where is Oncostellae based?

Oncostellae is headquartered in Santiago De Compostela, Spain, in the Europe region.

How does Oncostellae make money?

One revenue line is on record: licensing and Outlicensing.

Who are Oncostellae's main competitors?

Direct peers on record are Immunic Therapeutics, Landos Biopharma and Galapagos NV. Regional players are Oryzon Genomics and Palobiofarma. Broad incumbents are AbbVie, Pfizer and Eli Lilly. Emerging players are Theravance Biopharma and Dr. Falk Pharma.

Does Oncostellae have an API?

No public API is recorded for Oncostellae.

What industry is Oncostellae in?

Oncostellae's product category is Clinical-stage biopharmaceutical drug discovery. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WebcapitalriesgoCDTI Innovación y Bio & Tech Smart Capital FCRE (Noso Capital) invierten en OncostellaeCDTI Innovación and BIO & TECH SMART CAPITAL FCRE have invested in the Spanish biopharmaceutical company Oncostellae to fund the development of its drug candidates OST-499 and OST-664. The investment, which includes 500,000 euros from CDTI Innovación, will also support business development activities for licensing OST-122, a drug candidate that recently completed a successful Phase 2a trial for ulcerative colitis.Empresas de Capital Riesgo en EspaEl CDTI Innovación invierte, junto con BIO & TECH SMART CAPITAL FCRE, en ONCOSTELLAE, que desarrolla fármacos para el tratamiento de enfermedades con necesidades médicas no cubiertasCDTI Innovación and BIO & TECH SMART CAPITAL FCRE have entered into an agreement to invest in the Spanish biopharmaceutical company ONCOSTELLAE, with CDTI committing 500,000 euros. The investment will fund the continued development of drug candidates OST-499 and OST-664, as well as business development activities for OST-122, which recently demonstrated positive results in a Phase 2a trial for ulcerative colitis.CdtiThe CDTI Innovation invests, together with BIO & TECH SMART CAPITAL FCRE, ONCOSTELLAE S.L., who develops medicines for treatment of diseases with unmet medical needsCDTI Innovation and Bio & Tech Smart FCRE Capital have invested in the Spanish biopharmaceutical company Oncostellae S.L. to support its drug development programs. The investment, totaling €500,000 from CDTI Innovation alone alongside other partners, will fund the advancement of candidates OST-499 and OST-664, as well as business development for licensing OST-122.El Correo GallegoBio & Tech Smart Capital inyecta 500.000€ en Oncostellae y entra en el consejoOncostellae, a biopharmaceutical company based in Santiago, Spain, has secured 3.3 million euros in funding to complete phase 2 clinical trials for its drug OST-122 and advance OST-499 for colorectal cancer. Bio & Tech Smart Capital contributed 500,000 euros to the round and entered Oncostellae's board of directors as part of this investment. The funds will support ongoing research into inflammatory bowel disease and cancer treatments developed by the Galician firm.WebcapitalriesgoBio & Tech Smart Capital invierte medio millón de euros en la gallega OncostellaeBio & Tech Smart Capital FCRE has invested €500,000 in the Galician biopharmaceutical company Oncostellae, securing a seat on its board of administration. This investment is part of a larger funding round aimed at raising €3.3 million to complete phase 2 clinical trials for OST-122 and advance the cancer drug OST-499. The deal marks Bio & Tech Smart Capital's first portfolio entry, reinforcing its strategy to support life sciences projects in Galicia.ForbesOncostellae abre una ronda de 3,3 millones con la participación de Inveready y XesGaliciaBiofarmaceutical company Oncostellae has launched a funding round of 3.3 million euros to complete clinical trials for two molecules targeting digestive tract diseases. The investment is provided by venture capital firms Inveready, XesGalicia, FiTalent, and Unirisco, along with co-founder Julio Castro, while the remaining funds will be raised through the equity crowdfunding platform Capital Cell. The proceeds will enable the company to license one of its projects in 2024 or pursue a Series A raise to develop further licensing opportunities by 2026.WebcapitalriesgoOncostellae abre una ronda de €3,3M en la que participarán Inveready, XesGalicia, Fitalent, Unirisco y business angelsBiofarmaceutical company Oncostellae has opened a €3.3 million funding round to complete clinical trials for two molecules targeting gastrointestinal diseases. The investment includes contributions from venture capital firms Inveready, XesGalicia, FiTalent, and Unirisco, as well as equity crowdfunding platform Capital Cell. These funds will support the development of OST-122 and OST-499 towards potential licensing or Series A financing.OncostellaeNoviembre 2022La compañía gallega Oncostellae abre una ampliación de capital de 3,3 millones de euros para desarrollar un fármaco para la colitis ulcerosa y un segundo para el cáncer colorrectalSpanish biopharmaceutical company Oncostellae has launched a capital increase of 3.3 million euros to fund clinical trials for two drugs targeting ulcerative colitis and colorectal cancer. The funding is provided by venture capital firms Inveready, XesGalicia, FiTalent, Unirisco, co-founder Julio Castro, and the equity crowdfunding platform Capital Cell. Oncostellae aims to complete these trials and license its assets by 2024 or 2026.WebcapitalriesgoOncostellae cierra una ronda en la que participan Xesgalicia, Inveready, Fitalent y J.CastroOncostellae, a Santiago de Compostela biotech firm, closed a financing round with XesGalicia, Inveready, Fitalent, and Julio Castro, including a participative loan of up to 500,000 euros. The company, founded in 2013, develops compounds for inflammatory bowel disease, colon cancer, and immunological diseases, and is advancing clinical trials. The funding supports its first-in-class drug reaching clinical trials in Spanish hospitals.